Genomic Health Earnings: Here’s Why the Stock is Down Now

  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Genomic Health Inc. (NASDAQ:GHDX) had a loss and met Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 0.13%.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Genomic Health Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased to $-0.03 in the quarter versus EPS of $0.02 in the year-earlier quarter.

Revenue: Rose 7.92% to $63.1 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Genomic Health Inc. reported adjusted EPS loss of $0.03 per share. By that measure, the company missed the mean analyst estimate of $-0.03. It beat the average revenue estimate of $62.9 million.

Quoting Management: “The management of DCIS has been variable in the absence of reliable methods to select patients for treatment with surgical excision alone, without radiation. The DCIS Score is a new tool that can help physicians and patients make more informed decisions,” said Lawrence J. Solin, M.D., FACR, FASTRO, principal investigator for this study and chair of the Department of Radiation Oncology at Einstein Medical Center in Philadelphia, Pennsylvania. ”

Key Stats (on next page)…

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business